Endoscopy 2023; 55(S 02): S344
DOI: 10.1055/s-0043-1765987
Abstracts | ESGE Days 2023
ePoster

The role of EUS in evaluating pancreatic NET epidemiologic trends: a single center experience

A. Aversano
1   Gastroenterology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy
,
D. Macor
1   Gastroenterology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy
,
M. Carbone
1   Gastroenterology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy
,
E. Zucchi
1   Gastroenterology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy
,
M. Marino
1   Gastroenterology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy
,
M. Giuffrè
2   Patologie del fegato, Ospedale Cattinara, Trieste, Italy
,
S. L. Crocè
2   Patologie del fegato, Ospedale Cattinara, Trieste, Italy
,
D. Berretti
1   Gastroenterology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy
› Author Affiliations
› Further Information
Also available at
 
 

    Aims Pancreatic neuroendocrine neoplasms (pNENs) are a group of rare and clinically heterogeneous tumors and their incidence has been steadily raising worldwide. Improvements in endoscopic ultrasound (EUS) and in biopsy sampling have allowed better study and characterization of this neoplasm. The aim of this study is to evaluate the incidence, prevalence and temporal trends of pNENs in our single institution.

    Methods In this observational retrospective cohort study, we analyzed 109 patients based in the province of Udine (Italy) from 2009 to 2021 who underwent EUS-FNA of pNENs lesions. All statistical analyses were performed using R version 4.2.2 software.

    Results In our study females had lower incidence and longer survival rates than males. The incidence of pNENs increased from 0.55 per 100000 inhabitants in 2009 to 3.40 per 100000 inhabitants in 2018 (maximum incidence); the prevalence, instead, was 16.22 per 100000 inhabitants in the period of study. In 63.3% of the patients pNENs were an incidental finding. In most of the cases the patients had a localized disease. Compared to 2018 (peak of the number of diagnoses, 18), in 2020 under the SARS-CoV-2 pandemic we found a 44.4% reduction in the total number of diagnoses of pNENs (10). This confirms the negative effect of SARS-CoV-2 pandemic on highly-impacting diseases such as cancers [1].

    Conclusions There has been a steady increase in the incidence of pNENs with notable stage migration, as most patients are recently diagnosed in early stages of the disease.The SARSCoV-2 pandemic has reduced pNENs diagnoses, probably due to a decrease of first line imaging.


    #

    Conflicts of interest

    Authors do not have any conflict of interest to disclose.

    • 1 Dasari A, Shen C. et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3 (10) 1335-1342
      CrossrefPubMedSearch in Google Scholar

    Publication History

    Article published online:
    14 April 2023

    © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved.

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany

    • 1 Dasari A, Shen C. et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3 (10) 1335-1342
      CrossrefPubMedSearch in Google Scholar